Tesamorelin (10mg/vial)

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary gland to release the body's own natural growth hormone. By increasing pulsatile growth hormone secretion and downstream IGF-1 production, Tesamorelin has been extensively studied for its effects on body composition, visceral fat reduction, and metabolic health.

Clinical research has shown that Tesamorelin can significantly reduce visceral adipose tissue (VAT)—the deep abdominal fat surrounding internal organs—in individuals with HIV-associated lipodystrophy. Researchers continue to investigate its potential role in metabolic disorders, non-alcoholic fatty liver disease (NAFLD), healthy aging, and body composition. While these areas remain under investigation, Tesamorelin is one of the most extensively studied peptides affecting the growth hormone axis. It is important to note that Tesamorelin is not approved as a general weight-loss therapy, and its effects differ from medications designed specifically for obesity management.

Tesamorelin is approved by the U.S. FDA under the brand name Egrifta® for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Outside of this specific indication, its use remains investigational, and additional research is ongoing to better define its safety and effectiveness for other potential therapeutic applications.